TFA Therapeutics (RAJAF) Gross Margin (2020 - 2023)

TFA Therapeutics has reported Gross Margin for 4 years, with the latest figure at 90.22% in Q4 2023.

• On a quarterly basis, Gross Margin rose 120855.0% year-over-year to 90.22% in Q4 2023; TTM through Dec 2023 was 20.6%, a N/A change from a year earlier, with the FY2025 full-year figure at 61.09%, down 1123.0% from the prior year.
• Gross Margin was 90.22% for Q4 2023 at TFA Therapeutics, up from 1118.33% in the prior quarter.
• The five-year high for Gross Margin was 90.22% in Q4 2023, with the low at 2281.36% in Q4 2021.
• Average Gross Margin over 4 years is 809.91%, with a median of 524.25% recorded in 2020.
• The sharpest annual moves came in 2021 and 2023: Gross Margin sank 235118 bps in 2021, then jumped 120855 bps in 2023.
• Over 4 years, Gross Margin stood at 69.83% in 2020, then sank by 3367 bps to 2281.36% in 2021, then jumped by 51 bps to 1118.33% in 2022, then soared by 108 bps to 90.22% in 2023.
• The last three Gross Margin figures came in at 90.22% (Q4 2023), 1118.33% (Q4 2022), and 2281.36% (Q4 2021), per Business Quant data.